Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST10 in pulmonary hypertension associated with chronic lung disease
jRCT2031260503Phase 2Not yet recruiting
- Sponsor
- NeuPharma
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension due to lung disease (PH) and iron deficiency anemia (IDA) comparing Ferric maltol with Placebo (2 arms). Primary endpoint: Change from baseline in six-minute walk distance. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ferric maltol
03
Conditions
pulmonary hypertension due to lung disease (PH)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on jRCT2031260503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260503.